Telomerase activity in high-grade cervical lesions is associated with allelic imbalance at 6Q14-22

International Journal of Cancer

Volumn 105, Issue 5, 2003, Pages 577-582

  Van Duin, Mark ^a   Steenbergen, Renske D M ^a   De Wilde, Jillian ^a   Helmerhorst, Theo J M ^b   Verheijen, René H M ^a   Risse, Elle K J ^a   Meijer, Chris J L M ^a   Snuders, Peter J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Allelic imbalance; Cervical cancer; Chromosome 3p and 6q; HPV; Telomerase activity

Indexed keywords

DNA; MESSENGER RNA; TELOMERASE;

ADULT; ALLELIC IMBALANCE; ARTICLE; CANCER GRADING; CELL IMMORTALIZATION; CELL LINE; CELL LINE FK16A; CHROMOSOME 3P; CHROMOSOME 6P; CHROMOSOME 6Q; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; ALLELIC IMBALANCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 6; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENOME, VIRAL; HUMANS; KERATINOCYTES; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENIS; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TRANSFECTION; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0037499611     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11145     Document Type: Article

References (44)

1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. IARC. Monographs on the evaluation of the carcinogenic risks to humans. Lyon: IARC, 1995.
3. Durst M, Dzarlieva-Petrusevka T, Boukamp P, Fusenig NE, Gissman L. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1987;1:251-6.
4. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987;61:1061-6.
5. Steenbergen RDM, Walboomers JMM, Meijer CJLM, van der Raaij- Helmer EMH, Parker JN, Chow LT, Broker TR, Snijders PJF. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes toward immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996;13:1249-57.
6. Shay JW, Wright WE, Brasiskyte D, van der Haegen BA. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 1993;8:1407-13.
7. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-8.
8. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8:4099-105.
9. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-98.
10. Klingelhutz AJ, Foster SA, McDougal JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
11. Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus of human papillomavirus-transfected human cervical cells. Cancer Res 1993;53:1167-71.
12. Steenbergen RDM, Kramer D, Meijer CJLM, Walboomers JMM, Trott DA, Cuthbert AP, Newbold RF, Overkamp WJI, Zdzienicka MZ, Snijders PJF. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J Natl Cancer Inst 2001;93:865-72.
13. Backsch C, Wagenbach N, Nonn M, Leistritz S, Stanbridge E, Schneider A, Durst M. Microcell-mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity. Genes Chromosomes Cancer 2001;31:196-8.
14. Sedivy JM. Can ends justify the means?: telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells. Proc Natl Acad Sci USA 1998;95:9078-81.
15. Snijders PJF, van Duin M, Walboomers JMM, Steenbergen RDM, Risse EK, Helmerhorst ThJ, Verheijen RHM, Meijer CJLM. 1998.Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998;58:3812-8.
16. Wisman GBA, de Jong S, Meersma GJ, Helder MN, Hollema H, de Vries EGE, Nicol Keith W, van der Zee AGJ. Telomerase in (pre) neoplastic cervical disease. Hum Pathol 2000;31:1304-12.
17. Savelieva E, Belair CD, Newton MA, De Vries S, Gray JW, Waldman F, Reznikoff CA. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed uroepithelial cells. Oncogene 1997;14:551-60.
18. Cottage A, Dowen S, Roberts I, Pett M, Coleman N, Stanley M. Early genetic events in HPV immortalized keratinocytes. Genes Chromosomes Cancer 2001;30:72-9.
19. Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, Huettner PC. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 1998;22:57-65.
20. Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer 1999;26:346-54.
21. Wistuba II, Syed S, Behrens C, Duong M, Milchgrub S, Muller CY, Jagirdar J, Gazdar AF. Comparison of molecular changes in cervical intraepithelial neoplasia in HIV positive and HIV indeterminate subjects. Gynecol Oncol 1999;74:519-26.
22. Chatterjee A, Pulido HA, Koul S, Beleno N, Perilla A, Posso H, Manusukhani M, Murty VV. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res 2001;61:2119-23.
23. Chuaqui R, Silva M, Emmert-Buck M. Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma. Gynecol Oncol 2001;80:364-71.
24. Remmink AJ, Walboomers JMM, Helmerhorst ThJM, Voorhorst FJ, Rozendaal L, Risse EKJ, Meijer CJLM, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
25. Nobbenhuis MAE, Walboomers JMM, Helmerhorst ThJM, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJLM. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
26. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5/GP6 mediated PCR immunoassay method for rapid detection of 14 high risk and 6 low risk human papillomavirus genotypes in cervical scrapes. J Clin Microbiol 1997;35:791-5.
27. Collins A, Frezal J, Teague J, Morton NE. A metric map of humans: 23,500 loci in 850 bands. Proc Natl Acad Sci USA 1996;93:14771-5.
28. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:643-50.
29. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA. Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 2001;127:64-70.
30. Cuthbert AP, Bond J, Trott DA, Gill S, Broni J, Marriott A, Khoudoli G, Parkinson EK, Cooper CS, Newbold RF. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst. 1999;91:37-45.
31. Ohmura H, Tahara H, Suzuki M, Ide T, Shimizu M, Yoshida MA, Tahara E, Shay JW, Barrett JC, Oshimura M. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jpn J Cancer Res 1995;86:899-904.
32. Oh S, Song Y, Yim J, Kim TK, The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase transcriptase gene. J Biol Chem 1999;274:374-8.
33. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000;191:961-76.
34. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-Cabello F, Garrido F, Stern PL. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000;55:401-11.
35. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJF, Walboomers JMM, Hunter RD, Dyer PA, Stern PL. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405-11.
36. Cromme FV, Meijer CJLM, Snijders PJF, Uyterlinde A, Kenemans P, Helmerhorst ThJ, Stern PL, van den Brule AJC, Walboomers JMM. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 1993;8:2969-75.
37. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM, Walboomers JMM. Loss of transporter protein, encoded by the TAP-1 protein is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
38. Bontkes HJ, Walboomers JMM, Meijer CJLM, Helmerhorst ThJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998;351:187-8.
39. Simonic I, Gericke GS. The enigma of common fragile sites. Hum Genet 1996;97:524-31.
40. Sandhu AK, Kaur GP, Reddy DE, Rane NS, Athwal RS. A gene on 6q14-21 restores senescence to immortal ovarian tumor cells. Oncogene 1996;12:247-52.
41. Morelli C, Sherratt T, Trabanelli C, Rimessi P, Gualandi F, Greaves MJ, Negrini M, Boyle JM, Barbanti-Brodano G. Characterization of a 4-Mb region at chromosome 6q21 harboring a replicative sescence gene. Cancer Res 1997;57:4153-7.
42. Banga SS, Kim S, Hubbard K, Dasgupta T, Jha KK, Patsalis P, Hauptschein R, Gamberi B, DallaFavera R, Kraemer P, Ozer HL. SEN 6, a locus for SV40-mediated immortalization of human cells maps to 6q26-27. Oncogene 1997;14:313-21.
43. Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L. Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene 1999;18:1545-51.
44. Acquati F, Morelli C, Cinquetti R, Bianchi MG, Porrini D, Varesco L, Gismondi V, Roccheti R, Talevi S, Possati L, Magnanini C, Tibiletti MG, et al. Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene 2001;20:980-8.